Global Hemostasis and Tissue Sealing Agents Market

Hemostasis and Tissue Sealing Agents Market Size, Share, Growth Analysis, By Application(General surgery, minimally invasive surgery, and others), By End user(Hospitals, ambulatory surgical centres, home care settings, and others), By Region - Industry Forecast 2025-2032


Report ID: SQMIG35A2694 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 64 | Figures: 75

Hemostasis and Tissue Sealing Agents Market Dynamics

Hemostasis and Tissue Sealing Agents Market Drivers

Minimally Invasive Surgical Techniques

  • The growing preference for minimally invasive surgical techniques has boosted the demand for specialised hemostatic and tissue sealing agents suitable for use in laparoscopic, endoscopic, or robotic-assisted procedures. These agents play a vital role in ensuring effective hemostasis and tissue closure during less invasive surgeries.

Increasing Chronic Diseases

  • The rising incidence of chronic diseases, such as cardiovascular diseases, cancer, and diabetes, has contributed to the need for surgical interventions. Hemostasis and tissue sealing agents are crucial in managing bleeding and healing wounds associated with these conditions.

Hemostasis and Tissue Sealing Agents Market Restraints

Stringent Regulatory Approval Process

  • The approval process for new hemostasis and tissue sealing agents can be time-consuming and costly due to the strict regulatory requirements. This can hinder the entry of new products into the market and delay their commercialization.

High Cost of Advanced Products

  • Some advanced hemostatic and tissue sealing agents can be relatively expensive, impacting their adoption in regions with limited healthcare budgets or reimbursement constraints.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Hemostasis and Tissue Sealing Agents Market size was valued at USD 5.98 Billion in 2021 and is poised to grow from USD 6.4 Billion in 2022 to USD 11.08 Billion by 2030, at a CAGR of 7.1% during the forecast period (2023-2030).

The competitive landscape of the hemostasis and tissue sealing agents market is characterised by a diverse range of companies offering a variety of products to address the growing demand for effective hemostatic and tissue sealing solutions. These companies compete based on product innovation, efficacy, safety, regulatory approvals, and pricing. The market includes both established multinational corporations and smaller regional players, each striving to gain a competitive edge. Innovation plays a vital role in shaping the competitive landscape, with companies investing heavily in research and development to introduce new and advanced hemostasis and tissue sealing agents. These innovations often focus on improving product performance, reducing adverse reactions, and catering to specific surgical procedures or techniques, such as minimally invasive surgeries. 'Ethicon, Inc. - USA', 'Baxter International Inc. - USA', 'C.R. Bard, Inc. (acquired by BD/Becton Dickinson) - USA', 'Integra LifeSciences Holdings Corporation - USA', 'B. Braun Melsungen AG - Germany', 'Teleflex Incorporated -USA', 'Medtronic plc - Ireland', 'CryoLife, Inc. - USA', 'Smith & Nephew plc - United Kingdom', 'Pfizer Inc. (formerly Ethicon Biosurgery, a division of Ethicon, Inc.) - USA', 'Johnson & Johnson (Lifecell Corporation, a subsidiary) - USA', 'Cohera Medical, Inc. - USA', 'Pfizer Inc. (formerly King Pharmaceuticals, Inc.) - USA', 'Biom'Up - France', 'Hemostasis, LLC - USA', 'Tissuemed Ltd. - United Kingdom', 'The Medicines Company (acquired by Novartis) - USA', 'HyperBranch Medical Technology, Inc. (acquired by Stryker Corporation) - USA', 'Equimedical B.V. -: Netherlands', 'Ocular Therapeutix, Inc. -USA'

The growing preference for minimally invasive surgical techniques has boosted the demand for specialised hemostatic and tissue sealing agents suitable for use in laparoscopic, endoscopic, or robotic-assisted procedures. These agents play a vital role in ensuring effective hemostasis and tissue closure during less invasive surgeries.

Shift Towards Minimally Invasive Procedures: There has been a notable shift towards minimally invasive surgical techniques, which require specialised hemostasis and tissue sealing agents to ensure effective wound closure and tissue adhesion. As these procedures offer advantages such as smaller incisions, reduced scarring, and shorter recovery times, the demand for appropriate sealing agents has grown significantly.

The North American region, comprising the United States and Canada, holds a significant share of the Hemostasis and Tissue Sealing Agents market. The dominance of this region can be attributed to several factors, including a well-established healthcare infrastructure, high healthcare expenditure, and a large patient pool requiring surgical interventions. Moreover, the presence of key market players and their focus on research and development activities have contributed to the widespread adoption of advanced hemostatic and tissue sealing products. Additionally, the increasing prevalence of chronic diseases and the aging population have boosted the demand for surgical procedures, further driving the market's growth in North America.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Hemostasis and Tissue Sealing Agents Market

Report ID: SQMIG35A2694

$5,300
BUY NOW GET FREE SAMPLE